Clinical trials: PD-1 Inhibitor
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA)…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm
- Trial name
- NeoCamre-HN (NCT07400094)
- Testing
- Camrelizumab, Paclitaxel, carboplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Advanced Colorectal Cancer
Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer
This is a single-center, open-label, single-arm, exploratory phase II clinical trial designed to evaluate the preliminary efficacy and safety of sintilimab in combination with oral gossypol acetate in patients with advanced…
- Trial name
- NCT07656766
- Testing
- Sintilimab, Gossypol Acetate
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University People's Hospital
Urothelial Carcinoma Bladder, PD-1 Inhibitor
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
This is a phase II open label single-arm prospective study aiming to investigate the efficacy of PD-1 inhibitor Tislelizumab combined with conventional gemcitabine and cisplatin as bladder sparing treatment for patients with…
- Trial name
- NCT05401279
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Melanoma
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04305041
- Testing
- Pembrolizumab, Quavonlimab, Vibostolimab
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2 Positive Solid Tumors
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies
- Trial name
- NCT04460456
- Testing
- SBT6050, pembrolizumab, Cemiplimab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 58 people
- Sponsor
- Silverback Therapeutics
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it…
- Trial name
- NCT03666273
- Testing
- Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bayer
Non Small Cell Lung Carcinoma, c-MET
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide.
- Trial name
- NCT06772623
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab
- Where
- 126 sites in United States, Argentina and 14 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Esophageal Squamous Cell Carcinoma
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04767295
- Testing
- Camrelizumab, Albumin Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Hunan Cancer Hospital
Advanced Solid Tumors
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with…
- Trial name
- NCT07185243
- Testing
- recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer), Resistance to Immunotherapy
PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
This study evaluated the sintilimab combination of bevacizumab and tafolecimab in NSCLC patients who have previously been treated with anti- PD- 1/ligand (L)1 and acquired resistance.
- Trial name
- NCT07014215
- Testing
- Sintilimab combined with Bevacizumab and tafolecimab
- Volunteers
- 52 people
- Sponsor
- Anhui Provincial Cancer Hospital
Melanoma
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
Recent studies suggest that patients with metastatic melanoma whose gut microbiome is colonized by eubiotic bacteria have a stronger anti-cancer response to anti CTLA-4 and anti PD1.
- Trial name
- PICASSO (NCT04988841)
- Testing
- MaaT013, Ipilimumab, Nivolumab
- Where
- 5 sites in France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Solid Tumor, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors.
- Conditions
- Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety
- Trial name
- SCARCE (NCT05915481)
- Testing
- Cadonilimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or…
- Conditions
- Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer
- Trial name
- NCT04315701
- Testing
- Cemiplimab, Resection
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Resectable Esophageal Squamous Cell Carcinoma
Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC
This study is an open-label, prospective, cohort clinical study to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in…
- Trial name
- NCT06475196
- Testing
- Sintilimab (PD-1 inhibitor)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04828486
- Testing
- Futibatinib, Pembrolizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04411706
- Testing
- Sintilimab Combined With Apatinib and Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Xin-Hua Xu
Metastatic Breast Cancer
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to…
- Trial name
- KORNELIA (NCT04061863)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Bladder (Urothelial, Transitional Cell) Cancer
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
This is a prospective, open label, multicenter clinical study of vediximab combined with PD-1 and radiation therapy for bladder preservation in MIBC patients with HER-2 high expression (IHC 2+or 3+), conducted in accordance with…
- Trial name
- DECIDING (NCT07142200)
- Testing
- Disitamab Vedotin, PD-1 inhibitor, radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- RenJi Hospital